H.R. 2178 · 119th Congress
Cerebral Palsy Research Program Authorization Act of 2025
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Not yet voted on. This bill is still a proposal: it hasn't reached a floor vote, and its text can change in committee or on the floor before any vote.
8 cosponsors · 6 D, 2 R
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires the Centers for Disease Control and Prevention to carry out a research program that addresses diagnosis and treatment, public health surveillance, and other aspects of cerebral palsy (a group of disorders caused by abnormal brain development or brain damage that affects an individual's ability to move and maintain balance and posture).
What it does: CRS summary · Introduced in House · Mar 18, 2025
Cerebral Palsy Research Program Authorization Act of 2025
This bill requires the Centers for Disease Control and Prevention to carry out a research program that addresses diagnosis and treatment, public health surveillance, and other aspects of cerebral palsy (a group of disorders caused by abnormal brain development or brain damage that affects an individual's ability to move and maintain balance and posture).
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Cerebral Palsy Research Program Authorization Act of 2025
Latest action (Mar 18, 2025): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Mar 18, 2025
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.